Hexo: Canaccord Cuts Price Target In Half To $1.00

On December 14th, Hexo Corp (TSX: HEXO) reported its fiscal first quarter 2022 results. The company reported total net revenues of $50.2 million, an increase of 29% quarter over year. The company noted that Redecan and 48North contributed roughly $13.5 and $1.1 million to the companies total revenue for this quarter. Although, the company reported a gross loss of $32.8 million due to the company’s cost of goods sold being $83 million.

Additionally, the company announced that it expects to see $50 million in synergies from the acquisitions, a figure previously pegged at $35 million, and they are now forecasting positive cash flow within the next four quarters.

HEXO also reported during the quarter “transitory expenses” that come from a number of different impairments. The company reported a $23.8 million impairment of property, plant, and equipment and another $26.9 million investment impairment.

Subsequently, analysts lowered their 12-month price target on HEXO, bringing the 12-month average price target to C$2.27, or a 112% upside to the current stock price. There are 10 analysts covering the stock, with 1 analyst having a buy rating, 5 have hold ratings, 3 have sell ratings and 1 analyst has a strong sell rating. The street high sits at C$5.00 from Alliance Global Partners while the lowest comes in at $0.80.

In Canaccord’s fiscal first quarter review, they slash their 12-month price target in half, from C$2.00 to C$1.00, and reiterate their hold rating on the name, saying, “Declining organic growth, asset impairments, and an elevated debt burden point to a troubled start to FY22.”

Canaccord expects HEXO’s balance sheet to be an issue as the company ended the quarter with roughly C$56 million in unrestricted cash while the company had C$362 million of debt. Most notably, the company has a C$278 million senior convertible note outstanding. Canaccord says “if converted at current prices, would result in the issuance of >250M shares – a >70% increase from the company’s existing basic share count.”

For the results, the company missed every single one of Canaccord’s estimates, with the investment bank estimating revenue to be $53.77 million. While gross margins were expected to be $12.14 million and adjusted EBITDA was estimated at ($9.76) million.

Canaccord says that the HEXO saw an organic decline in revenue of roughly 10% and their sale data points to flat or negative growth for many of the company’s brands this year. Specifically, the company saw a >50% decrease reduction in Alberta due to “a significant reduction in its Original Stash value flower in the period.”

Below you can see Canaccord’s updated fiscal full-year 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why This Mexico Silver Project Still Has Room to Grow | Daniel Rodriguez – Mercado Minerals

This Gold Project Took Years to Matter — Now the Timing Looks Right | Grande Portage PEA

The Uranium Supply Gap Is Getting Harder to Ignore | Leigh Curyer of NexGen Energy

Recommended

Antimony Resources Expands Footprint as Soil Sampling Lights Up Ground South of Bald Hill

Mercado Drills 256 g/t Silver Over 6.5 Metres In First Drill Hole of Inaugural Program

Related News

Stifel Releases Third Quarter Earning Preview For US Multi State Operators

Last week Stifel released their Q3 earnings preview for all the MSO’s while stating that...

Sunday, November 1, 2020, 01:43:00 PM

Cameco: Canaccord Refers To Firm As “Go-To” Name For Uranium Exposure

On February 9th, Cameco (TSX: CCO) reported its full-year 2021 financial results. The company reported...

Saturday, February 12, 2022, 02:03:00 PM

Curaleaf: Cormark Upgrades To Buy Rating, Canaccord, Haywood Raise Price Targets

After Curaleaf’s (CSE: CURA) record-breaking second-quarter numbers, analysts have upgraded their twelve-month price targets. Curaleaf...

Wednesday, August 19, 2020, 11:29:55 AM

Organigram: Haywood Lowers Price Target To $3.00

On November 23rd, Organigram Holdings (TSX: OGI) announced its fourth quarter fiscal 2021 results. The...

Monday, November 29, 2021, 10:15:00 AM

Snowflake: Canaccord Expects Long Term Guidance Of $10 Billion In Revenues To Remain Intact

Snowflake (NYSE: SNOW) last week reported its third-quarter financial results. The company announced that product...

Sunday, December 4, 2022, 01:24:00 PM